Organic Revenue Growth: 6% year-over-year increase. Adjusted EBITDA Margin: Expanded by 400 basis points year-over-year. Sample Management Solutions Revenue: Grew 8% on an organic basis. Multiomics Revenue: Grew 3% on an organic basis. Non-GAAP EPS: $0.05 per share. Free Cash Flow: $7 million for the quarter. Cash and Equivalents: $540 million at the end of the quarter. Non-GAAP Gross Margin: 47.5%, up 130 basis points year-over-year. Sample Management Solutions Gross Margin: 49.7%, up 340 basis points year-over-year. Multiomics Gross Margin: 44.9%, down 140 basis points year-over-year. Next Generation Sequencing Growth: 20% year-over-year increase. Plasma D Revenue: More than doubled compared to the same period last year.

Warning! GuruFocus has detected 1 Warning Sign with AZTA.

Release Date: May 07, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Azenta Inc (NASDAQ:AZTA) reported a solid second quarter with a 6% year-over-year organic revenue growth and a 400 basis point expansion in adjusted EBITDA margin. The company maintained its full-year 2025 guidance of 3% to 5% organic revenue growth and 300 basis points of adjusted EBITDA margin expansion. Azenta Inc (NASDAQ:AZTA) has a strong financial position with $540 million in cash and no debt, allowing for potential acquisitions and investments in digital capabilities. The company is actively evaluating potential acquisitions to accelerate revenue growth and margin expansion, indicating a proactive approach to growth opportunities. Azenta Inc (NASDAQ:AZTA) has implemented operational improvements, including the Azenta Business System, to enhance efficiency and drive long-term value creation.

Negative Points

The company faces macroeconomic challenges, including tariffs, funding headwinds for US academic research, and geopolitical tensions, which could impact future performance. NIH funding reductions are expected to result in a 1% headwind to revenues, although countermeasures have been put in place to mitigate the impact. There was a decline in gene synthesis revenue by 10% year-over-year, attributed to a difficult comparison and a slowdown in North America. Sanger sequencing revenue declined by 18% year-over-year due to the industry's transition to newer sequencing technologies. Despite improvements, Azenta Inc (NASDAQ:AZTA) acknowledges that it is not yet where it needs to be in terms of customer-facing performance metrics, quality, and on-time delivery.

Q & A Highlights

Q: How should we think about the cadence of growth in the back half of the year versus the first half, considering the 1% impact from funding? A: John Marotta, CEO, explained that they are holding their guidance and have cleared the 1% risk on NIH funding. Lawrence Lin, CFO, added that the 2025 quarterly revenue profiles shouldn't differ significantly from the prior year, with the third and fourth quarters expected to align with previous years despite macroeconomic challenges.

Story Continues

Q: Can you provide more details on the SMS leadership transition and whether you're looking internally or externally for a new leader? A: John Marotta, CEO, mentioned that David's departure was due to personal reasons. He is directly overseeing the SMS business, emphasizing its importance as the crown jewel of the company. They are focusing on different business segments within SMS to drive growth.

Q: What are the assumptions behind the 1% NIH funding headwind, and where is the offset coming from? A: John Marotta, CEO, stated that they have countermeasured the NIH funding risk completely. They engaged with academic customers to understand their perspectives and pivoted towards pharma and biotech to offset the impact. Lawrence Lin, CFO, added that the NIH funding issue presents an opportunity for Azenta to win market share as less efficient core labs may close or scale back.

Q: Is the impressive free cash flow performance in the first half sustainable, and what about the margin expansion in the second half? A: Lawrence Lin, CFO, explained that the free cash flow was driven by better working capital execution and a tax refund. They are optimistic about achieving their long-term target of $100 million in free cash flow. The margin expansion guidance considers some tariff impacts, with a step-down due to stock compensation and bonus releases.

Q: How is Azenta positioned in the China market, considering the US-China dialogue and its impact on biotech innovation? A: John Marotta, CEO, highlighted that Azenta's business in China is growing, with gene synthesis up 8% in the market. They have adapted to a regional go-to-market model, allowing their China business to operate like a local company, which has been effective in maintaining growth despite geopolitical tensions.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.